Lifeboat Foundation

Senescent cell removal is the first true rejuvenation therapy to treat one of the aging processes and with human clinicial trials in the next 18 months these are some very exciting times. Here is yet another study showing natural compounds can be used in combination with drugs to kill senescent cells.

Today’s open access research paper outlines the discovery of yet another new candidate drug for the selective destruction of senescent cells. This is an increasingly popular research topic nowadays. Senescent cells perform a variety of functions, but on the whole they are bad news. Cells become senescent in response to stresses or reaching the Hayflick limit to replication. They cease further division and start to generate a potent mix of signals, the senescence-associated secretory phenotype or SASP, that can provoke inflammation, disarray the surrounding extracellular matrix structures, and change behavior of nearby cells for the worse. Then they destroy themselves, or are destroyed by the immune system — for the most part at least. This is helpful in wound healing, and in small doses helps to reduce cancer incidence by removing those cells most at risk of becoming cancerous. Unfortunately a growing number of these cells linger without being destroyed, more with every passing year, and their presence eventually causes significant dysfunction. That in turn produces age-related disease, frailty, and eventually death. Senescent cells are not the only root cause of aging, but they provide a significant contribution to the downward spiral of health and wellbeing, and even only their own would eventually produce death by aging.

The beneficial aspects of senescent cells seem to require only a transient presence, so the most direct approach to the problem presented by these cells is to destroy them every so often. Build a targeted therapy capable of sweeping senenscent cells from tissues, and make it efficient enough to keep the count of such cells low. That is the way to prevent senescent cells form contributing to age-related disease. Working in mice, researchers have produced results such as functional rejuvenation in aged lungs and extended life span through the targeted destruction of senescent cells. Since perhaps only a few percent of the cells in old tissue are senescent, this targeted destruction can be accomplished with few side-effects beyond those generated by off-target effects of the medication itself.

Continue reading “Piperlongumine as a Senolytic Drug Candidate with Fewer Side-Effects” »

A new biomarker for Alzheimers could improve the patient outcome and allow for earlier treatment.

An enzyme found in the fluid around the brain and spine is giving researchers a snapshot of what happens inside the minds of Alzheimer’s patients and how that relates to cognitive decline.

Iowa State University researchers say higher levels of the enzyme, autotaxin, significantly predict memory impairment and Type 2 diabetes. Just a one-point difference in autotaxin levels — for example, going from a level of two to a three — is equal to a 3.5 to 5 times increase in the odds of being diagnosed with some form of memory loss, said Auriel Willette, an assistant professor of food science and human nutrition at Iowa State.

Continue reading “New biomarker predicts Alzheimer’s disease and link to diabetes” »

New study provides deeper insight into the immune system.

In a bid to better understand the gene expression patterns that control T cell activity, researchers at the La Jolla Institute for Allergy and Immunology mapped genome-wide changes in chromatin accessibility as T cells respond to acute and chronic virus infections. Their findings, published in the Dec. 20, 2016 issue of Immunity, shed light on the molecular mechanisms that determine the fate of T lymphocytes and open new approaches to clinical intervention strategies to modulate T cell activity and improve immune function.

“Identifying the different factors that determine different T cell states and therefore their function helps us understand if T cells will be able or not to fight viral infections or tumor growth, and if they will be able or not to provide long-term protection,” says the study’s first author James Scott-Browne, a postdoctoral fellow in the laboratory of Anjana Rao, a professor in the Division of Signaling and Gene Expression. “We may be able to revert the exhaustion phenotype of T cells and render them better able to fight tumors or chronic viral infections such as HIV, or generate better memory cells in response to vaccines.”

Continue reading “Researchers map genome-wide changes that drive T cell maturation and exhaustion” »

Stanford University’s amazing new regenerative medicine facility where the impossible is becoming possible.

The 25,000-square-foot facility, which opened last September, puts Stanford at the forefront of one of medicine’s most important and promising trends: regenerative medicine, which aims to refurbish diseased or damaged tissue using the body’s own healthy cells.

“We’re curing the incurable,” said laboratory director David DiGiusto, who holds a doctorate.

Continue reading “Stanford manufactures gene-engineered cells to cure the incurable” »

Decline of the immune system is one of the areas SENS are working on, with just over a week left for the Winter Fundraiser and Triple donation match now is the time to support their work!

Immunosenescence is a key process in aging and rejuvention or replacement of the thymus which gradually wastes away as we age exposing us to pathogens is an important step in dealing with age-related diseases. SENS is working on these problems so if you want to see solutions please consider donating to our Winter Fundraiser today on the link below:

http://www.sens.org/donate

Continue reading “Immune Restoration Results from Placing a Young Thymus into an Aged Mouse” »

Light therapy kills cancer in new no surgery, no chemo approach.

A new non-surgical treatment for low-risk prostate cancer can effectively kill cancer cells while preserving healthy tissue, reports a new UCL-led phase III clinical trial in 413 patients. The trial was funded by STEBA Biotech which holds the commercial license for the treatment.

The new treatment, ‘vascular-targeted photodynamic therapy’ (VTP), involves injecting a light-sensitive drug into the bloodstream and then activating it with a laser to destroy tumour tissue in the prostate. The research, published in The Lancet Oncology, found that around half (49%) of patients treated with VTP went into complete remission compared with 13.5% in the control group.

Continue reading “Light therapy effectively treats early prostate cancer” »

The biotech battle between China and the US has begun as we predicated when we announced the first CRISPR deployment in humans last month. The US has upped the ante and is taking a step further in the race for the biotech crown. All great news for us as the more competition the faster progress will move so let’s hope there is a fierce battle for biotech coming.

In 2015, a little girl called Layla was treated with gene-edited immune cells that eliminated all signs of the leukemia that was killing her. Layla’s treatment was a one-off, but by the end of 2017, the technique could have saved dozens of lives.

It took many years to develop the gene-editing tool that saved Layla, but thanks to a revolutionary method known as CRISPR, this can now be done in just weeks.

Continue reading “CRISPR gene editing human trials in China and US offer hope for countless lives” »

Google Tech Talk with the SENS Research Foundation!

Commentary about our recent Google Tech Talk about the MitoSENS project from FightAging!

“As the clock ticks on this year’s SENS rejuvenation research fundraiser — less than two weeks to go now, and plenty left in the matching fund for new donations — it is good to be reminded of the progress that the SENS Research Foundation has accomplished with the charitable funding of recent years. With that in mind, today I’ll point you to a recent Google Tech Talk that provides a layperson’s introduction to one of the projects that our community has funded, fixing the problem of mitochondrial damage in aging. The point of the SENS (Strategies for Engineered Negligible Senescence) research programs is to accelerate progress towards specific forms of therapy that can bring aging under medical control.”

Continue reading “Presenting Mitochondrial Rejuvenation at a Google Tech Talk” »

Aging as a disease or Uber-disease is gaining traction and pressure is mounting on the WHO to include it as it fits their definition of a disease state.

Failing to classify aging as a disease is slowing progress and costing lives. We need to change the paradigm.